Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum

Paras Biopharmaceuticals Finland Oy, an upcoming biopharmaceutical manufacturing company for biosimilars and therapeutic peptides, announced today that it has been selected to present at the Cavendish Global Health Impact Forum taking place 10th – 14th May in La Jolla, California, USA.

The purpose of the Cavendish Global Health Impact Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Cavendish Impact Forums are hosted by leading institutions around the world including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our La Jolla, California Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Paras Biopharmaceuticals’ technologies (Diabrid? Technology, NobleCleav? Technolgy and Biomultifold? Microbial High Expression Technolgy) and scientific insights for the development of affordable biologics allows them to make a major contribution in targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.

“We are honoured to be selected as the first Finnish company (and only the second company in the Nordic region) to present at this unique event. Recognition of our efforts for the effective production of recombinant therapeutics to provide affordable healthcare affecting populations around the world,” said Dr. Hans Soderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals.

“In a time of widespread economic austerity and increased pressure on Governments’ health budgets, demand for access to affordable healthcare is greater than ever. We welcome the opportunity to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world,” said Dr Ashesh Kumar, Director of Biologics and Licensing at Paras Biopharmaceuticals.

About Paras Biopharmaceuticals (http://www.parasbiopharma.com)

Based in Oulu, Finland, Paras Biopharmaceuticals is an award winning, privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Our facilities (European GMP US-FDA compliant) in Finland are dedicated to the development, scale-up and GMP production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.

About Cavendish Global (http://cavendishglobal.com)

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavours within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California.

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2015/04/1430230930.jpeg

Media Contact
Company Name: Paras Biopharmaceuticals Finland Oy
Contact Person: Dr Mark Jackson
Email: mark.jackson@parasbiopharma.com
Phone: 00358442905993
Address:Kiviharjunlenkki 2
City: Oulu
Country: Finland
Website: www.parasbiopharma.com

Source: ABNewswire

ReleaseID: 27382